![Yposkesi sélectionné pour la Grande Exposition du Fabriqué en France à l’Elysée les 18 et 19 janvier 2020](https://ala.associates/wp-content/uploads/2022/04/15-janvier-2020.jpg)
![Yposkesi sélectionné pour la Grande Exposition du Fabriqué en France à l’Elysée les 18 et 19 janvier 2020](https://ala.associates/wp-content/uploads/2022/04/15-janvier-2020.jpg)
![Urania Therapeutics benefits from €1.7M Deeptech financing from Bpifrance](https://ala.associates/wp-content/uploads/2022/04/14-janvier-2020-mr-de-face.jpg)
Urania Therapeutics benefits from €1.7M Deeptech financing from Bpifrance
![Domain Therapeutics secures €6 million ($6.7M) debt financing](https://ala.associates/wp-content/uploads/2022/04/13-janvier-2020.png)
Domain Therapeutics secures €6 million ($6.7M) debt financing
![Yposkesi selected to produce clinical and large-scale commercial material of micro-dystrophin for Genethon and Sarepta Therapeutics program](https://ala.associates/wp-content/uploads/2022/04/9-janvier-2020.jpg)
Yposkesi selected to produce clinical and large-scale commercial material of micro-dystrophin for Genethon and Sarepta Therapeutics program
![Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD](https://ala.associates/wp-content/uploads/2022/04/9-janvier-2020-FDA.png)
Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD
![Alderaan Biotechnology raises €18.5M in Series A from Advent France Biotechnology (AFB) and Medicxi](https://ala.associates/wp-content/uploads/2022/04/9-janvier-2020-Mr.png)
Alderaan Biotechnology raises €18.5M in Series A from Advent France Biotechnology (AFB) and Medicxi
![Domain Therapeutics and Pr Michel Bouvier (IRIC Montreal) receive the RSRI award for bioSens-All™ project at ADRIQ-RCTi Innovation Prize gala](https://ala.associates/wp-content/uploads/2022/04/17-decembre-2019.jpeg)
Domain Therapeutics and Pr Michel Bouvier (IRIC Montreal) receive the RSRI award for bioSens-All™ project at ADRIQ-RCTi Innovation Prize gala
Advent France Biotechnology participe au tour d’amorçage de 4,2 millions d’euros d’Augustine Therapeutics
![Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia](https://ala.associates/wp-content/uploads/2022/04/12-nov-mex.jpg)
Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia
![Urania Therapeutics closes a €3.5M initial seed round](https://ala.associates/wp-content/uploads/2022/04/6-novembre.jpg)